Artwork

Content provided by NeurologyLive® Mind Moments®. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NeurologyLive® Mind Moments® or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

106: Potential Role of Stathmin-2 in Amyotrophic Lateral Sclerosis

18:34
 
Share
 

Manage episode 394963252 series 3340456
Content provided by NeurologyLive® Mind Moments®. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NeurologyLive® Mind Moments® or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, provided comment on a recently published study which unveiled that stathmin-2 loss leads to neurofilament-dependent axonal collapse in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the potential of this protein as a disease-modifying biomarker and whether it may be incorporated in trials in the near future.
Looking for more neuromuscular discussion? Check out the NeurologyLive® neuromuscular clinical focus page.
Episode Breakdown:
  • 1:15 – Idea behind studying stathmin-2
  • 2:45 – Overviewing study results
  • 7:05 – Next steps in extending this research
  • 8:40 – Neurology News Minute
  • 11:30 – Stathmin-2's connection with neurofilament light
  • 12:55 – Potential of stathmin-2 as ALS-specific biomarker
  • 14:45 – Future use of stathmin-2 in clinical trials
  • 15:30 – Closing thoughts

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
  continue reading

128 episodes

Artwork
iconShare
 
Manage episode 394963252 series 3340456
Content provided by NeurologyLive® Mind Moments®. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NeurologyLive® Mind Moments® or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, provided comment on a recently published study which unveiled that stathmin-2 loss leads to neurofilament-dependent axonal collapse in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the potential of this protein as a disease-modifying biomarker and whether it may be incorporated in trials in the near future.
Looking for more neuromuscular discussion? Check out the NeurologyLive® neuromuscular clinical focus page.
Episode Breakdown:
  • 1:15 – Idea behind studying stathmin-2
  • 2:45 – Overviewing study results
  • 7:05 – Next steps in extending this research
  • 8:40 – Neurology News Minute
  • 11:30 – Stathmin-2's connection with neurofilament light
  • 12:55 – Potential of stathmin-2 as ALS-specific biomarker
  • 14:45 – Future use of stathmin-2 in clinical trials
  • 15:30 – Closing thoughts

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
  continue reading

128 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide